https://www.selleckchem.com/products/LBH-589.html
Median time to hospital discharge was shorter in the NAC arm (9 days; IQR 6-15) than in the placebo arm (18 days; IQR 10-25), hazard ratio 1.73 (95% CI 1.13-2.65). Mortality was 14% overall and did not differ by study arm. The study infusion was stopped early due to an adverse reaction in 5 participants receiving NAC [nausea and vomiting (3), anaphylaxis (1), pain at drip site (1)]. NAC did not shorten time to ALT100 U/L in participants with AT-DILI, but significantly reduced length of hospital stay. NAC should be considered in man
Like
Comment
Share
